TY - JOUR
T1 - Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies
AU - Tsimberidou, Apostolia Maria
AU - Alvarado, Yesid
AU - Giles, Francis J.
PY - 2002/8
Y1 - 2002/8
N2 - Ribonucleotide reductases catalyze the de novo biosynthesis of deoxyribonucleosides for DNA synthesis. Increased ribonucleotide reductases activity has been associated with malignant transformation and tumor cell growth. The ribonucleotide reductases inhibitors may bind with the R1 subunit of the enzyme (Class 1) or the nonheme iron (Class 2). This review focuses on the therapeutic use of ribonucleotide reductases inhibitors in hematologic malignancies. Hydroxyurea, fludarabine and cladribine have established roles in the management of hematologic malignancies, while other ribonucleotide reductases inhibitors, such as gemcitabine, tezacitabine and heterocyclic carboxaldehyde thiosemicarbazones (e.g., triapine) are being evaluated in clinical trials.
AB - Ribonucleotide reductases catalyze the de novo biosynthesis of deoxyribonucleosides for DNA synthesis. Increased ribonucleotide reductases activity has been associated with malignant transformation and tumor cell growth. The ribonucleotide reductases inhibitors may bind with the R1 subunit of the enzyme (Class 1) or the nonheme iron (Class 2). This review focuses on the therapeutic use of ribonucleotide reductases inhibitors in hematologic malignancies. Hydroxyurea, fludarabine and cladribine have established roles in the management of hematologic malignancies, while other ribonucleotide reductases inhibitors, such as gemcitabine, tezacitabine and heterocyclic carboxaldehyde thiosemicarbazones (e.g., triapine) are being evaluated in clinical trials.
KW - Hematologic malignancies
KW - Inhibitors
KW - Ribonucleotide reductase
UR - http://www.scopus.com/inward/record.url?scp=0036684318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036684318&partnerID=8YFLogxK
U2 - 10.1586/14737140.2.4.437
DO - 10.1586/14737140.2.4.437
M3 - Review article
C2 - 12647987
AN - SCOPUS:0036684318
SN - 1473-7140
VL - 2
SP - 437
EP - 448
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 4
ER -